尿核基质蛋白-22测定在膀胱癌中的临床应用
|
摘要
目的:研究分析尿核基质蛋白-22测定在膀胱癌诊断中的应用价值。方法:随机抽取我院2015年9月~2016年3月收治的疑似膀胱癌患者50例作为研究对象,采用酶联免疫法对其尿样中的核基质蛋白-22水平进行测定,并行尿脱落细胞学检查,分别计算两种方法检查时患者的诊断阳性率。以患者的最终组织病理学诊断结果为依据,对核基质蛋白-22水平测定与尿脱落细胞学检查诊断膀胱癌的灵敏度、特异性、准确度进行计算,同时分析核基质蛋白-22水平与膀胱癌患者病理分级之间的相关性。结果:核基质蛋白-22水平测定、尿脱落细胞检查诊断膀胱癌的阳性率分别为66.00%和16.00%,检测灵敏度分别为86.67%、40.00%,特异性分别为42.86%、94.29%,准确度分别为56.00%、78.00%,核基质蛋白-22水平测定在检测阳性率、灵敏度上均显著高于尿脱落细胞检查,而检测特异性和准确度低于尿脱落细胞检查,差异均有统计学意义(P<0.05)。在组织病理学检查确诊为膀胱癌的患者中,核基质蛋白-22检测水平随病理分级的升高而升高,且各级检测结果的比较差异均有统计学意义(P<0.05)。结论:核基质蛋白-22测定应用于膀胱癌的筛查中,具有较高的灵敏度,且其检测水平与膀胱癌患者的病理分级之间存在显著相关性,可以将其作为膀胱癌的首选筛查方法,颇具临床应用价值。
Objective: To study the value of urinary nu clear matrix protein-22 determination in the diagnosis of bladder cancer.Methods: From September 2015 to March 2017, 50 suspected bladder cancer patients were randomly selected as the research subjects, by using the method of enzyme-linked immune, the level of nuclear matrix protein-22 in the urine samples were determined, exfoliative urine cytology was also used, the patient's diagnosis positive rates were calculated for two methods respectively. On the basis of the final histopathologic diagnosis, the sensitivity, specificity and accuracy for diagnosis of bladder cancer by the nuclear matrix protein-22 level determination and exfoliative urine cytology examination were compared, at the same time the correlation between the nuclear matrix protein-22 level and pathology classification of patients with bladder cancer was analyzed. Results: The positive rate for the diagnosis of bladder cancer was 66.00% and 16.00%, respectively by the nuclear matrix protein-22 determination and exfoliated urine cytology and the sensitivity were 86.67%, 40.00%, the specificity of 42.86%, 94.29% and the accuracy of 56.00%, 78.00% respectively, the positive rate and the sensitivity of the nuclear matrix protein-22 determination were significantly higher than those of exfoliated urine cytology, but the specificity and the total accuracy were lower than those of exfoliated urine cytology, the differences were statistically significant(P <0.05). In the patients diagnosed by histopathological examination the level of nuclear matrix protein-22 increased when the pathological grade rose, and the differences of test results were statistically significant among different grades(P <0.05). Conclusion: The nuclear matrix protein-22 determination has high sensitivity in bladder cancer screening, there is a significant correlation between the test level and the pathological grading of bladder cancer. It can be as the preferred method for screening of bladder cancer, and has clinical value.
Objective: To study the value of urinary nu clear matrix protein-22 determination in the diagnosis of bladder cancer.Methods: From September 2015 to March 2017, 50 suspected bladder cancer patients were randomly selected as the research subjects, by using the method of enzyme-linked immune, the level of nuclear matrix protein-22 in the urine samples were determined, exfoliative urine cytology was also used, the patient's diagnosis positive rates were calculated for two methods respectively. On the basis of the final histopathologic diagnosis, the sensitivity, specificity and accuracy for diagnosis of bladder cancer by the nuclear matrix protein-22 level determination and exfoliative urine cytology examination were compared, at the same time the correlation between the nuclear matrix protein-22 level and pathology classification of patients with bladder cancer was analyzed. Results: The positive rate for the diagnosis of bladder cancer was 66.00% and 16.00%, respectively by the nuclear matrix protein-22 determination and exfoliated urine cytology and the sensitivity were 86.67%, 40.00%, the specificity of 42.86%, 94.29% and the accuracy of 56.00%, 78.00% respectively, the positive rate and the sensitivity of the nuclear matrix protein-22 determination were significantly higher than those of exfoliated urine cytology, but the specificity and the total accuracy were lower than those of exfoliated urine cytology, the differences were statistically significant(P <0.05). In the patients diagnosed by histopathological examination the level of nuclear matrix protein-22 increased when the pathological grade rose, and the differences of test results were statistically significant among different grades(P <0.05). Conclusion: The nuclear matrix protein-22 determination has high sensitivity in bladder cancer screening, there is a significant correlation between the test level and the pathological grading of bladder cancer. It can be as the preferred method for screening of bladder cancer, and has clinical value.
引文
[1]李辉英.尿核基质蛋白-22和液基细胞学在血尿患者膀胱癌筛查中的应用[J].广东微量元素科学,2016,23(7):42-44
[2]梁安坡,张玉香,张金庄.尿NMP22及Cox-2蛋白含量检测对浅表性膀胱癌电切术后复发的预判价值研究[J].海南医学院学报,2015,21(12):1716-1718
[3]吴静,方克伟.尿液中核基质蛋白22联合端粒酶活性检测诊断膀胱癌的实验研究[J].现代肿瘤医学,2013,21(3):595-598
[4]毕长富,张克荣,董浩,等.尿核基质蛋白22测定在膀胱癌诊断中的应用价值[J].河北医药,2010,32(14):1847-1848
[5]杨青,李俊,梁朝朝,等.核基质蛋白22联合尿脱落细胞学检查对膀胱癌诊断的价值[J].安徽医科大学学报,2012,47(2):220-222
[6]崔国兴.尿端粒酶、NMP22和Immuno Cyt联合检测在膀胱癌诊断中的应用[J].现代泌尿外科杂志,2013,18(2):145-148
[7]刘民,刘胜,赵万里,等.尿肿瘤标志物联合检测在膀胱癌早期诊断中的应用价值[J].河北医药,2011,33(2):179-180
[8]李盛宽,邓耀良,刘德云,等.尿核基质蛋白在膀胱癌中的临床意义[J].广西医科大学学报,2013,30(5):682-685
[2]梁安坡,张玉香,张金庄.尿NMP22及Cox-2蛋白含量检测对浅表性膀胱癌电切术后复发的预判价值研究[J].海南医学院学报,2015,21(12):1716-1718
[3]吴静,方克伟.尿液中核基质蛋白22联合端粒酶活性检测诊断膀胱癌的实验研究[J].现代肿瘤医学,2013,21(3):595-598
[4]毕长富,张克荣,董浩,等.尿核基质蛋白22测定在膀胱癌诊断中的应用价值[J].河北医药,2010,32(14):1847-1848
[5]杨青,李俊,梁朝朝,等.核基质蛋白22联合尿脱落细胞学检查对膀胱癌诊断的价值[J].安徽医科大学学报,2012,47(2):220-222
[6]崔国兴.尿端粒酶、NMP22和Immuno Cyt联合检测在膀胱癌诊断中的应用[J].现代泌尿外科杂志,2013,18(2):145-148
[7]刘民,刘胜,赵万里,等.尿肿瘤标志物联合检测在膀胱癌早期诊断中的应用价值[J].河北医药,2011,33(2):179-180
[8]李盛宽,邓耀良,刘德云,等.尿核基质蛋白在膀胱癌中的临床意义[J].广西医科大学学报,2013,30(5):682-685